{
    "organizations": [],
    "uuid": "aefef543ae447abbec761f8da4afb6b5cc582936",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-hikma-signs-licensing-agreement-wi/brief-hikma-signs-licensing-agreement-with-rovi-for-enoxaparin-biosimilar-idUSFWN1S10D9",
    "ord_in_thread": 0,
    "title": "BRIEF-Hikma Signs Licensing Agreement With Rovi For Enoxaparin Biosimilar",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " Hikma Pharmaceuticals Plc:\n* HIKMA EXPANDS LICENSING AGREEMENT WITH ROVI * SIGNED A LICENSING AGREEMENT WITH LABORATORIOS FARMACEÚTICOS ROVI SA FOR THEIR ENOXAPARIN BIOSIMILAR\n* UNDER TERMS OF AGREEMENT, HIKMA HAS EXCLUSIVE RIGHTS TO DISTRIBUTE AND MARKET ENOXAPARIN ACROSS ITS MENA MARKETS. Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-24T16:02:00.000+03:00",
    "crawled": "2018-04-25T14:39:30.014+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "hikma",
        "pharmaceutical",
        "plc",
        "hikma",
        "expands",
        "licensing",
        "agreement",
        "rovi",
        "signed",
        "licensing",
        "agreement",
        "laboratorios",
        "farmaceúticos",
        "rovi",
        "sa",
        "enoxaparin",
        "biosimilar",
        "term",
        "agreement",
        "hikma",
        "exclusive",
        "right",
        "distribute",
        "market",
        "enoxaparin",
        "across",
        "mena",
        "market",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}